In Personalized Selection of Immunotherapy Strategies in Metastatic NSCLC and Future Evidence Gaps, our experts delve into ...
This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...
Ivonescimab combined with chemotherapy showed significant progression-free survival benefits in advanced squamous NSCLC patients, including both PD-L1-positive and PD-L1-negative populations. The ...
Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with ...
Amivantamab is a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor, demonstrating efficacy in patients with non–small cell lung cancer ...
According to a bridging analysis, two PD-L1 immunohistochemical assays — Dako 22C3 and VENTANA SP263 — demonstrated 88% concordance in identifying patients with non-small cell lung cancer (NSCLC) for ...
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, ...
In July 2025, the FDA greenlit the use of sunvozertinib (Zegfrovy) for pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 ...
Caris Life Sciences aims to standardize MET immunohistochemistry testing for non-squamous non-small cell lung cancer to enhance molecular insights and treatment personalization. MET protein expression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results